NEW

Philips Partners with DiA Imaging Analysis

Royal Philips and DiA Imaging Analysis Ltd., a provider of AI-powered applications for ultrasound, have announced a strategic partnership* to deliver automated solutions to clinicians at the point-of-care.

Philips spotlights new solutions at ECR 2021

Royal Philips has announced its participation in the European Congress of Radiology (ECR) virtual event, March 3-7, 2021, where the company will feature new and enhanced diagnostic and interventional solutions that further expand its Radiology Workflow Suite, connecting data, technology and people across the imaging enterprise.

Epsilon Imaging Partners with Siemens Healthineers

Epsilon Imaging, a visualization and analysis software provider transforming cardiac diagnostic workflow with strain imaging, has announced a partnership with Siemens Healthineers, a leading developer of medical imaging and information management solutions, to offer syngo Dynamics users EchoInsight visualization and analysis with strain imaging.

iRad Announces a Distributorship Agreement with FUJIFILM Medical Systems

iRad, Innovative Radiology Equipment Sales and Services, LLC has announced a distributorship agreement with FUJIFILM Medical Services.

FDA Approves Seno Medical’s Breast Cancer Diagnostic Technology

Seno Medical’s Imagio Breast Imaging System uses non-invasive opto-acoustic ultrasound (OA/US) technology to provide information on suspicious breast lesions in real time, helping providers characterize and differentiate masses that may – or may not – require more invasive diagnostic evaluation.

The Center for Devices and Radiological Health (CDRH) of the U.S. Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions. The company’s Imagio Breast Imaging System uses non-invasive opto-acoustic ultrasound (OA/US) technology to provide information on suspicious breast lesions in real time, helping providers characterize and differentiate masses that may – or may not – require more invasive diagnostic evaluation.

Breast biopsy procedures caused by false-positive diagnostic assessments in the United States cost the health care system more than $2 billion per year. Seno’s Imagio technology could mitigate that by giving providers additional real-time information regarding suspicious breast masses and increased confidence to make a better decision regarding the need for diagnostic breast biopsies.

The company’s OA/US technology combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging. The opto-acoustic images provide a unique blood map in and around breast masses, while the ultrasound provides a traditional anatomical image. Through the appearance or absence of two hallmark indicators of cancer – angiogenesis and deoxygenation – Seno Medical has shown that the Imagio OA/US Breast Imaging system will be a more effective tool to help radiologists confirm or rule out malignancy compared to traditional diagnostic imaging modalities – without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents. In addition to the novel imaging provided by the Imagio system, Seno includes an AI physician decision support tool (the SenoGram) to aid in interpreting the new images that, along with training and certification, help radiologists make the transition from ultrasound alone to OA/US Imaging.

The system is indicated for use by trained and qualified health care providers to evaluate palpable and non-palpable breast abnormalities in adult patients who are referred for diagnostic imaging breast work-up following clinical presentation or other imaging examinations such as screening mammography.

Seno’s Chief Executive Officer Tom Umbel commented, “We are thrilled to have reached this milestone and are looking forward to moving our technology platform forward in the U.S. with this FDA approval. Our internal team and our faithful investigators and clinical trial sites have worked diligently to bring Imagio to market and improve care for patients and providers with the precise diagnostic capabilities and enhanced decision-making support that our novel OA/US imaging provides.”

For more information, visit www.SenoMedical.com.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *